PROGgeneV2 - Pan Cancer Prognostics Database


# | CANCER | DATASET | DESCRIPTION | TOTAL SAMPLES | TOTAL GENES |
---|---|---|---|---|---|
1 | ADRENAL | GSE19776 | GSE19776 - Adrenocortical Carcinoma Gene Expression Profiling | 22 | 21933 |
2 | ADRENAL | GSE33371 | GSE33371 - Beta-catenin status effects in human adrenocortical carcinomas (33), adenomas (22), and normal adrenal cortex (10) | 23 | 21212 |
3 | ADRENAL | TCGA-ACC | ![]() |
79 | 16907 |
4 | BLADDER | GSE13507 | GSE13507 - Predictive Value of Prognosis-Related Gene Expression Study in Primary Bladder Cancer | 165 | 24357 |
5 | BLADDER | GSE19915 | GSE19915 - Subtype classification, grading, and outcome prediction of urothelial carcinomas by combined mRNA profiling and aCGH | 144 | 2506 |
6 | BLADDER | GSE31684 | GSE31684 - Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer | 93 | 21702 |
7 | BLADDER | GSE48276 | GSE48276 - Gene expression profiling of urothelial carcinoma | 73 | 20717 |
8 | BLADDER | TCGA-BLCA | TCGA BLADDER CARCINOMA DATA | 123 | 15448 |
9 | BONE | GSE21257 | GSE21257 - Genome-wide gene expression profiling on pre-chemotherapy biopsies of osteosarcoma patients | 53 | 24996 |
10 | BRAIN | GSE13041_U133 | GSE13041 - Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age | 191 | 13480 |
11 | BRAIN | GSE13041_U95v2 | GSE13041 - Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age | 49 | 9383 |
12 | BRAIN | GSE16011 | GSE16011 - Intrinsic Gene Expression Profiles of Gliomas are a Better Predictor of Survival than Histology | 262 | 21212 |
13 | BRAIN | GSE16581 | GSE16581 - Genomic landscape of meningiomas: gene expression | 67 | 21703 |
14 | BRAIN | GSE2817 | GSE2817 - Wavelet modelling of microarray data provides chromosomal pattern of expression which predicts survival in gliomas | 25 | 21703 |
15 | BRAIN | GSE30074 | GSE30074 - Expression data from 30 medulloblastomas | 30 | 21103 |
16 | BRAIN | GSE37418 | GSE37418 - Novel mutations target distinct subgroups of medulloblastoma. | 75 | 21703 |
17 | BRAIN | GSE42669 | GSE42669 - Patient specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ (gene expression) | 55 | 21092 |
18 | BRAIN | GSE4271_U133A | Molecular subclasses of high-grade glioma: prognosis, disease progression, and neurogenesis | 77 | 13720 |
19 | BRAIN | GSE4271_U133B | Molecular subclasses of high-grade glioma: prognosis, disease progression, and neurogenesis | 78 | 10688 |
20 | BRAIN | GSE4412_U133A | freij-affy-human-91666 | 83 | 13720 |
21 | BRAIN | GSE4412_U133B | freij-affy-human-91666 | 83 | 10688 |
22 | BRAIN | GSE7696 | GSE7696 - Glioblastoma from a homogenous cohort of patients treated within clinical trial | 77 | 21212 |
23 | BRAIN | TCGA-GBM | TCGA DATA GLIOBLASTOMA MULTIFORME | 577 | 17813 |
24 | BRAIN | TCGA-LGG | TCGA LOWER GRADE GLIOMA DATA | 206 | 16467 |
25 | BREAST | GSE10886-GPL1390 | ![]() |
104 | 6378 |
26 | BREAST | GSE10893-GPL1390 | ![]() |
149 | 4929 |
27 | BREAST | GSE10893-GPL887 | ![]() |
51 | 10463 |
28 | BREAST | GSE11121 | GSE11121 - The humoral immune system has a key prognostic impact in node-negative breast cancer | 200 | 13480 |
29 | BREAST | GSE12093 | GSE12093 - The 76-gene Signature Defines High-Risk Patients that Benefit from Adjuvant Tamoxifen Therapy | 132 | 13476 |
30 | BREAST | GSE1379 | GSE1379 - breast cancer / tamoxifen monotherapy (whole tissue tumor biopsies) | 60 | 15369 |
31 | BREAST | GSE1456_U133A | GSE1456_U133A - Gene expression of breast cancer tissue in a large population-based cohort of Swedish patients | 159 | 13480 |
32 | BREAST | GSE1456_U133B | GSE1456_U133B - Gene expression of breast cancer tissue in a large population-based cohort of Swedish patients | 159 | 9856 |
33 | BREAST | GSE16987 | ![]() |
146 | 14359 |
34 | BREAST | GSE17705 | GSE17705 - Endocrine Sensitivity Index Validation Dataset | 298 | 13480 |
35 | BREAST | GSE18229-GPL1390 | ![]() |
160 | 4844 |
36 | BREAST | GSE18229-GPL887 | ![]() |
53 | 10460 |
37 | BREAST | GSE19536-GPL6480 | ![]() |
113 | 16505 |
38 | BREAST | GSE19615 | GSE19615 - Integrated genomic and function characterization of the 8q22 gain | 115 | 21212 |
39 | BREAST | GSE19783-GPL6480 | ![]() |
111 | 16625 |
40 | BREAST | GSE2034 | GSE2034 - Breast cancer relapse free survival | 286 | 13480 |
41 | BREAST | GSE21653 | ![]() |
247 | 16523 |
42 | BREAST | GSE22133-GPL5345 | ![]() |
349 | 5926 |
43 | BREAST | GSE22219 | ![]() |
215 | 9867 |
44 | BREAST | GSE22226-GPL1708 | ![]() |
128 | 10354 |
45 | BREAST | GSE25055 | ![]() |
309 | 12079 |
46 | BREAST | GSE25065 | ![]() |
197 | 12079 |
47 | BREAST | GSE2603 | GSE2603 - Subpopulations of MDA-MB-231 and Primary Breast Cancers | 82 | 13480 |
48 | BREAST | GSE2607-GPL1390 | ![]() |
47 | 5951 |
49 | BREAST | GSE2607-GPL887 | ![]() |
38 | 11863 |
50 | BREAST | GSE2990 | GSE2990 - Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis | 101 | 13480 |
51 | BREAST | GSE3143 | ![]() |
157 | 8684 |
52 | BREAST | GSE3494_U133A | GSE3494_U133A - An expression signature for p53 in breast cancer predicts mutation status, transcriptional effects, and patient survival | 236 | 13480 |
53 | BREAST | GSE3494_U133B | GSE3494_U133B - An expression signature for p53 in breast cancer predicts mutation status, transcriptional effects, and patient survival | 236 | 9856 |
54 | BREAST | GSE37181 | ![]() |
122 | 14406 |
55 | BREAST | GSE37751 | GSE37751 - Molecular Profiles of Human Breast Cancer and Their Association with Tumor Subtypes and Disease Prognosis (Affymetrix) | 60 | 21093 |
56 | BREAST | GSE42568 | GSE42568 - Breast Cancer Gene Expression Analysis | 104 | 21703 |
57 | BREAST | GSE46563 | ![]() |
93 | 14406 |
58 | BREAST | GSE48390 | ![]() |
80 | 16523 |
59 | BREAST | GSE48408 | GSE48408 - Long non-coding RNA HOTAIR is an independent prognostic marker of metastasis in estrogen receptor positive primary breast cancer | 164 | 21793 |
60 | BREAST | GSE4922_U133A | GSE4922_U133A - Genetic Reclassification of Histologic Grade Delineates New Clinical Subtypes of Breast Cancer | 249 | 13480 |
61 | BREAST | GSE4922_U133B | GSE4922_U133B - Genetic Reclassification of Histologic Grade Delineates New Clinical Subtypes of Breast Cancer | 248 | 9856 |
62 | BREAST | GSE53031 | ![]() |
166 | 17306 |
63 | BREAST | GSE5327 | GSE5327 - Breast cancer relapse free survival and lung metastasis free survival | 58 | 13480 |
64 | BREAST | GSE58812 | ![]() |
106 | 16523 |
65 | BREAST | GSE6130-GPL1390 | ![]() |
66 | 5568 |
66 | BREAST | GSE6130-GPL887 | ![]() |
33 | 11720 |
67 | BREAST | GSE6532_U133_P2 | GSE6532_U133_P2 - Definition of clinically distinct molecular subtypes in estrogen receptor positive breast carcinomas using genomic grade | 87 | 21212 |
68 | BREAST | GSE6532_U133A | GSE6532_U133A - Definition of clinically distinct molecular subtypes in estrogen receptor positive breast carcinomas using genomic grade | 189 | 13480 |
69 | BREAST | GSE6532_U133B | GSE6532_U133B - Definition of clinically distinct molecular subtypes in estrogen receptor positive breast carcinomas using genomic grade | 126 | 9856 |
70 | BREAST | GSE7390 | GSE7390 - Strong Time Dependence of the 76-Gene Prognostic Signature | 198 | 13480 |
71 | BREAST | GSE9195 | GSE9195 - Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen | 77 | 21212 |
72 | BREAST | GSE9893 | ![]() |
154 | 7404 |
73 | BREAST | NKI | NKI - A gene-expression signature as a predictor of survival in breast cancer | 295 | 11475 |
74 | BREAST | TCGA-BRCA | TCGA - TCGA BREAST CANCER DATA | 596 | 17813 |
75 | CERVICAL | GSE44001 | GSE44001 - Genetic profiling to predict recurrence of early cervical cancer | 300 | 20669 |
76 | CERVICAL | TCGA-CESC | ![]() |
281 | 17503 |
77 | COLORECTAL | GSE12945 | GSE12945 - Expression data from colorectal cancers | 62 | 13720 |
78 | COLORECTAL | GSE14333 | GSE14333 - Expression data from 290 primary colorectal cancers | 187 | 21703 |
79 | COLORECTAL | GSE16125 | GSE16125 - Integrative approach for prioritizing cancer genes in sporadic colon cancer | 32 | 14984 |
80 | COLORECTAL | GSE17536 | GSE17536 - Metastasis Gene Expression Profile Predicts Recurrence and Death in Colon Cancer Patients | 174 | 21212 |
81 | COLORECTAL | GSE17537 | GSE17537- Metastasis Gene Expression Profile Predicts Recurrence and Death in Colon Cancer Patients | 52 | 21212 |
82 | COLORECTAL | GSE24551 | GSE24551 - Exon level expression profiling of colorectal cancer tissue samples | 160 | 14984 |
83 | COLORECTAL | GSE28722 | GSE28722 - EMT is the dominant program in human colon cancer (Agilent) | 125 | 15218 |
84 | COLORECTAL | GSE28814 | GSE28814 - EMT is the dominant program in human colon cancer | 122 | 15240 |
85 | COLORECTAL | GSE29621 | GSE29621 - mRNA and microRNA profile in colon cancer [mRNA data] | 65 | 21703 |
86 | COLORECTAL | GSE30378 | GSE30378 - Gene level expression profiling of colorectal cancer tissue samples (test sample series) | 95 | 14984 |
87 | COLORECTAL | GSE31595 | GSE31595 - Gene Expression Profiles in Stage II and III Colon Cancer. Application of a 128-gene signature | 37 | 21703 |
88 | COLORECTAL | GSE38832 | ![]() |
121 | 16523 |
89 | COLORECTAL | GSE39582 | ![]() |
578 | 16523 |
90 | COLORECTAL | GSE41258 | GSE41258 - Expression data from colorectal cancer patients | 182 | 13720 |
91 | COLORECTAL | TCGA-COAD | TCGA DATA COLON ADENOCARCINOMA | 121 | 17813 |
92 | ESOPHAGUS | GSE19417 | GSE19417 - Human esophageal adenocarcinomas | 70 | 17367 |
93 | ESOPHAGUS | TCGA-ESCA | ![]() |
180 | 18077 |
94 | EYE | GSE22138 | GSE22138 - Expression Data from Uveal Melanoma primary tumors. | 63 | 21703 |
95 | EYE | GSE39717 | GSE39717 - Gene expression analysis of uveal melanoma tumor tissue | 30 | 21454 |
96 | EYE | TCGA-UVM | ![]() |
77 | 16577 |
97 | GASTRIC | GSE15459 | ![]() |
186 | 16523 |
98 | GASTRIC | GSE26253 | ![]() |
431 | 11579 |
99 | GASTRIC | GSE34942 | ![]() |
55 | 16523 |
100 | GASTRIC | GSE62254 | ![]() |
299 | 16523 |
101 | HEME | GSE10846 | GSE10846 - Prediction of survival in diffuse large B cell lymphoma treated with chemotherapy plus Rituximab | 414 | 21703 |
102 | HEME | GSE12417_U133A | GSE12417 - Prognostic gene signature for normal karyotype AML - Affy U133A Samples | 163 | 13480 |
103 | HEME | GSE12417_U133B | GSE12417 - Prognostic gene signature for normal karyotype AML - Affy U133B Samples | 162 | 9856 |
104 | HEME | GSE12417_U133P2 | GSE12417 - Prognostic gene signature for normal karyotype AML - Affy U133plus2 Samples | 79 | 21212 |
105 | HEME | GSE16131_U133A | Differences Between Follicular Lymphoma With and Without Translocation t(14;18) | 180 | 13719 |
106 | HEME | GSE16131_U133B | Differences Between Follicular Lymphoma With and Without Translocation t(14;18) | 180 | 10686 |
107 | HEME | GSE22762_U133A | An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia | 44 | 13719 |
108 | HEME | GSE22762_U133B | An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia | 44 | 10684 |
109 | HEME | GSE22762_U133P2 | An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia | 107 | 21703 |
110 | HEME | GSE23501 | GSE23501 - DNA methylation signatures define molecular subtypes of Diffuse Large B Cell Lymphoma | 69 | 21703 |
111 | HEME | GSE2658 | GSE2658 - Gene Expression Profiles of Multiple Myeloma | 546 | 21703 |
112 | HEME | GSE4475 | GSE4475 - A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling | 158 | 13719 |
113 | HEME | TCGA-AML | TCGA DATA ACUTE MYELOID LEUKEMIA | 157 | 21212 |
114 | HNC | GSE10300 | GSE10300 - head and neck squamous cell carcinoma samples | 43 | 21703 |
115 | HNC | GSE27020 | ![]() |
108 | 12079 |
116 | HNC | GSE65858 | ![]() |
269 | 14493 |
117 | HNC | TCGA HEAD AND NECK SQUAMOUS CELL CARCINOMA DATA | 291 | 17187 | |
118 | HNC | E-MTAB-1328 | E-MTAB-1328 - Methylome, transcriptome and miRNome profiling by array and high throughput sequencing of 89 patients with head and neck squamous cell carcinoma | 60 | 21703 |
119 | LIVER | GSE10141 | GSE10141 - Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma | 80 | 6100 |
120 | LIVER | GSE17856 | GSE17856 - Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive HCC | 43 | 14293 |
121 | LIVER | GSE27150 | GSE27150 - Transcriptional profile of human liver tissues: hepatocellular carcinoma vs. matched noncancerousliver tissue | 81 | 2456 |
122 | LIVER | TCGA-LIHC | ![]() |
293 | 16873 |
123 | LUNG | GSE11117 | GSE11117 - Molecular Classification and Prediction of Survival in Non-Small-Cell Lung Cancer | 41 | 9601 |
124 | LUNG | GSE11969 | GSE11969 - Expression Profile-Defined Classification of Lung Adenocarcinoma | 90 | 16531 |
125 | LUNG | GSE13213 | GSE13213 - Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis | 117 | 30469 |
126 | LUNG | GSE14814 | GSE14814 - Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non-Small Cell Lung Cancer | 88 | 13481 |
127 | LUNG | GSE17710 | GSE17710 - Human lung squamous cell carcinoma expression profiling | 56 | 17083 |
128 | LUNG | GSE19188 | GSE19188 - Expression data for early stage NSCLC | 82 | 21703 |
129 | LUNG | GSE26939 | GSE26939 - Human lung adenocarcinoma mRNA expression and gene mutations | 115 | 17108 |
130 | LUNG | GSE30219 | GSE30219 - Off-context gene expression in lung cancer identifies a group of metastatic-prone tumors | 282 | 21703 |
131 | LUNG | GSE31210 | GSE31210 - Gene expression data for pathological stage I-II lung adenocarcinomas | 226 | 21703 |
132 | LUNG | GSE3141 | GSE3141 - Lung Cancer Dataset | 111 | 21703 |
133 | LUNG | GSE37745 | GSE37745 - Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis and tissue microarray validation | 96 | 21703 |
134 | LUNG | GSE41271 | GSE41271 - Expression profiling of 275 lung cancer specimens | 275 | 25428 |
135 | LUNG | GSE42127 | GSE42127 - Expression data for non-small-cell lung cancer | 176 | 25428 |
136 | LUNG | GSE4573 | GSE4573 - Gene expression signatures for predicting prognosis of squamous cell lung carcinomas | 130 | 13480 |
137 | LUNG | GSE50081 | GSE50081 - Validation of a histology-independent prognostic gene signature for early stage, non-small cell lung cancer including stage IA patients | 181 | 21703 |
138 | LUNG | GSE5843 | GSE5843 - Expression profiling defines a recurrence signature in lung adenocarcinoma | 48 | 12089 |
139 | LUNG | GSE8894 | GSE8894 - Prediction of Recurrence-Free Survival in Postoperative NSCLC Patients - a Useful Prospective Clinical Practice | 138 | 21213 |
140 | LUNG | TCGA-LUAD | TCGA DATA LUNG ADEMOCARCINOMA | 150 | 20502 |
141 | LUNG | TCGA-LUSC | TCGA DATA LUNG SQUAMOUS CELL CARCINOMA | 120 | 17813 |
142 | MESOTHELIOMA | TCGA-MESO | ![]() |
85 | 17580 |
143 | NEURO-ENDOCRINE | GSE62564 | ![]() |
497 | 18440 |
144 | NEURO-ENDOCRINE | TCGA-PCPG | ![]() |
175 | 17374 |
145 | OVARIAN | GSE13876 | ![]() |
414 | 13462 |
146 | OVARIAN | GSE14764 | GSE14764 - A Prognostic Gene Expression Index in Ovarian Cancer | 79 | 13480 |
147 | OVARIAN | GSE17260 | GSE17260 - Prediction of progression-free survival in patients with advanced-stage serous ovarian cancer | 110 | 19566 |
148 | OVARIAN | GSE18520 | GSE18520 - Whole-genome oligonucleotide expression analysis of papillary serous ovarian adenocarcinomas | 53 | 21703 |
149 | OVARIAN | GSE19829_U133P2 | GSE19829 - A gene expression profile of BRCAness that is associated with outcome in ovarian cancer. AffyU133plus2 Samples | 26 | 21212 |
150 | OVARIAN | GSE19829_U95V2 | GSE19829 - A gene expression profile of BRCAness that is associated with outcome in ovarian cancer. AffyU95v2 Samples | 39 | 9383 |
151 | OVARIAN | GSE23554 | GSE23554 - Ovarian Cancer Dataset | 28 | 13719 |
152 | OVARIAN | GSE26712 | GSE26712 - A Gene Signature Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer | 185 | 13480 |
153 | OVARIAN | GSE30161 | GSE30161 - Genomic Multivariate Predictors of Response to Adjuvant Chemotherapy in Ovarian Carcinoma: Predicting Platinum Resistance | 58 | 21703 |
154 | OVARIAN | GSE31245 | GSE31245 - Unique gene expression profile based upon pathologic response in epithelial ovarian cancer | 55 | 9651 |
155 | OVARIAN | GSE32062 | GSE32062 - Immune-activation as a therapeutic direction for patients with high-risk ovarian cancer based on gene expression signature | 260 | 19595 |
156 | OVARIAN | GSE32063 | GSE32063 - Immune-activation as a therapeutic direction for patients with high-risk ovarian cancer based on gene expression signature (2) | 40 | 19566 |
157 | OVARIAN | GSE49997 | GSE49997 - Validating the Impact of a Molecular Subtype in Epithelial Ovarian Cancer (EOC) on Progression Free and Overall Survival | 194 | 16726 |
158 | OVARIAN | GSE63885 | ![]() |
74 | 16523 |
159 | OVARIAN | GSE73614 | ![]() |
106 | 15789 |
160 | OVARIAN | GSE8841 | ![]() |
82 | 1415 |
161 | OVARIAN | GSE8842 | GSE8842 - ANALYSIS OF GENE EXPRESSION IN EARLY-STAGE OVARIAN CANCER | 78 | 5631 |
162 | OVARIAN | GSE9891 | GSE9891 - Expression profile of 285 ovarian tumour samples | 276 | 21212 |
163 | OVARIAN | TCGA-OVAD | TCGA DATA OVARIAN ADENOCARCINOMA | 578 | 12042 |
164 | PANCREAS | GSE21501 | GSE21501 - A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma | 102 | 19680 |
165 | PANCREAS | GSE28735 | GSE28735 - Microarray gene-expression profiles of 45 matching pairs of pancreatic tumor and adjacent non-tumor tissues from 45 patients with pancreatic ductal adenocarcinoma | 42 | 21096 |
166 | PANCREAS | GSE50827 | ![]() |
32 | 16928 |
167 | PANCREAS | GSE57495 | ![]() |
63 | 17043 |
168 | PANCREAS | GSE71729 | ![]() |
124 | 15758 |
169 | PANCREAS | TCGA-PAAD | ![]() |
170 | 17997 |
170 | PROSTATE | GSE16560 | GSE16560 - Molecular Sampling of Prostate Cancer: a dilemma for predicting disease progression | 281 | 6100 |
171 | PROSTATE | GSE26022 | ![]() |
70 | 472 |
172 | PROSTATE | GSE26242 | ![]() |
78 | 472 |
173 | PROSTATE | GSE40272 | GSE40272 - Gene-expression profiling of prostate tumors | 67 | 9371 |
174 | PROSTATE | GSE70768 | ![]() |
110 | 16928 |
175 | PROSTATE | GSE70769 | ![]() |
91 | 16930 |
176 | PROSTATE | TCGA-PRAD | ![]() |
413 | 17682 |
177 | RECTUM | TCGA_READ | TCGA DATA RECTAL ADENOCARCINOMA | 42 | 17728 |
178 | RENAL | GSE29609 | GSE29609 - Clear-cell renal cell carcinomas tumors | 39 | 18841 |
179 | RENAL | TCGA-KIRC | TCGA DATA KIDNEY CLEAR CELL CARCINOMA | 528 | 20502 |
180 | RENAL | TCGA-KICH | ![]() |
66 | 17131 |
181 | RENAL | TCGA-KIRC | ![]() |
234 | 17652 |
182 | RENAL | TCGA-KIRP | ![]() |
220 | 17357 |
183 | SARCOMA | TCGA-SARC | ![]() |
234 | 17382 |
184 | SKIN | GSE19234 | GSE19234 - Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. | 44 | 21703 |
185 | SKIN | GSE22153 | GSE22153 - Gene Experssion Profiling-Based Identification of Molecular Subtypes in Stage IV Melanoma with Different Clinical Outcome (test set) | 57 | 24614 |
186 | SKIN | GSE53118 | GSE53118 - BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma | 79 | 17617 |
187 | SKIN | TCGA-SKCM | TCGA SKIN CUTANEOUS MELANOMA DATA | 163 | 15341 |
188 | STOMACH | TCGA-STAD | TCGA DATA STOMACH ADENOCARCINOMA | 18 | 20512 |
189 | THYMUS | TCGA-THYM | ![]() |
119 | 17652 |
190 | THYROID | TCGA-THCA | ![]() |
476 | 17410 |
191 | UTERUS | TCGA-UTED | TCGA DATA UTERINE ENDOMETRIAL CARCINOMA | 54 | 17813 |
192 | UTERUS | TCGA-UCEC | ![]() |
143 | 17620 |
193 | UTERUS | TCGA-UCS | ![]() |
55 | 18011 |